Andrew A. Davis

953 total citations
23 papers, 494 citations indexed

About

Andrew A. Davis is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Andrew A. Davis has authored 23 papers receiving a total of 494 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 15 papers in Cancer Research and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Andrew A. Davis's work include Cancer Genomics and Diagnostics (12 papers), Cancer Cells and Metastasis (8 papers) and Advanced Breast Cancer Therapies (7 papers). Andrew A. Davis is often cited by papers focused on Cancer Genomics and Diagnostics (12 papers), Cancer Cells and Metastasis (8 papers) and Advanced Breast Cancer Therapies (7 papers). Andrew A. Davis collaborates with scholars based in United States, Italy and Belgium. Andrew A. Davis's co-authors include Virginia Kaklamani, Young Kwang Chae, Alan Pan, Kirtee Raparia, Francis J. Giles, Nisha Mohindra, Maria Matsangou, Sarita Agte, Victoria Villaflor and Su Yun Chung and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Andrew A. Davis

22 papers receiving 489 citations

Peers

Countries citing papers authored by Andrew A. Davis

Since Specialization

Citations

This map shows the geographic impact of Andrew A. Davis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew A. Davis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew A. Davis more than expected).

Fields of papers citing papers by Andrew A. Davis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew A. Davis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew A. Davis. The network helps show where Andrew A. Davis may publish in the future.

Co-authorship network of co-authors of Andrew A. Davis

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew A. Davis. A scholar is included among the top collaborators of Andrew A. Davis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew A. Davis. Andrew A. Davis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract PS08-03: Sequencing Antibody-Drug Conjugate after Antibody-Drug Conjugate in Metastatic Breast Cancer (A3 study): Multi-Institution Experience and Biomarker Analysis 2024 ·Cancer Research ·Rachel O. Abelman, Laura M. Spring, Geoffrey Fell, Andrew A. Davis, (unknown), (unknown), Neelima Vidula, Seth A. Wander, Arielle J. Medford, Jennifer J. Shin, Elizabeth Abraham, Steven J. Isakoff, Beverly Moy, Leif W. Ellisen, Aditya Bardia	16
2	Radiologic imaging biomarkers in triple-negative breast cancer: a literature review about the role of artificial intelligence and the way forward 2024 ·PubMed ·(unknown), Qi Xiao, José Marcio Luna, (unknown), (unknown), Foluso O. Ademuyiwa, Andrew A. Davis, Debbie L. Bennett, Aimilia Gastounioti	2
3	Abstract PO4-18-02: Real-world (RW) utilization and patient outcomes across three CDK4/6 inhibitors in metastatic breast cancer (mBC) 2024 ·Cancer Research ·Caroline Weipert, Seth A. Wander, Andrew A. Davis, (unknown), Jayati Saha, Jiemin Liao, Nicole Zhang, Daniel G. Stover, Aditya Bardia, Massimo Cristofanilli	1
4	Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis 2023 ·JCO Precision Oncology ·Lorenzo Gerratana, Andrew A. Davis, (unknown), Carolina Reduzzi, Katherine Clifton, (unknown), (unknown), Ami N. Shah, (unknown), Charles S. Dai, Paolo D’Amico, Firas Wehbe, Arielle J. Medford, Seth A. Wander, William J. Gradishar, Amir Behdad, X. Cynthia, Fabio Puglisi, Aditya Bardia, Massimo Cristofanilli	7
5	ESR1 mutational landscape and impact of co-existing resistance variants on clinical outcomes in patients with metastatic breast cancer. 2023 ·Journal of Clinical Oncology ·Arielle J. Medford, Ignaty Leshchiner, (unknown), Lesli A. Kiedrowski, Andrzej Niemierko, (unknown), Seth A. Wander, Laura M. Spring, Neelima Vidula, Charles S. Dai, Steven J. Isakoff, Lorenzo Gerratana, Ami N. Shah, Andrew A. Davis, Massimo Cristofanilli, Beverly Moy, Leif W. Ellisen, Gad Getz, Aditya Bardia	1
6	Circulating Tumor Cells Prediction in Hormone Receptor Positive HER2-Negative Advanced Breast Cancer: A Retrospective Analysis of the MONARCH 2 Trial 2023 ·The Oncologist ·Lorenzo Gerratana, Masha Kocherginsky, Andrew A. Davis, Paolo D’Amico, Carolina Reduzzi, Fabio Puglisi, Massimo Cristofanilli	4
7	Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab 2022 ·Breast Cancer Targets and Therapy ·Nusayba A. Bagegni, Andrew A. Davis, Katherine Clifton, Foluso O. Ademuyiwa	19
8	Abstract P2-07-02: Genomic predictors of rapid progression to first line endocrine and CDK4/6 inhibitor combination therapy in patients with estrogen receptor positive (ER+) HER-2 negative (HER2-) advanced breast cancer (ABC) 2022 ·Cancer Research ·(unknown), Lorenzo Gerratana, Andrew A. Davis, (unknown), Katherine Clifton, Ami N. Shah, Paolo D’Amico, Charles S. Dai, (unknown), X. Cynthia, Seth A. Wander, Dejan Juric, Massimo Cristofanilli, Bruce A. Chabner, Aditya Bardia	1
9	Circulating tumor cells, circulating tumor DNA, and disease characteristics in young women with metastatic breast cancer 2021 ·Breast Cancer Research and Treatment ·Ami N. Shah, (unknown), Lorenzo Gerratana, Chenyu Lin, Andrew A. Davis, Qiang Zhang, Saya Jacob, Brian S. Finkelman, Youbin Zhang, (unknown), Paolo D’Amico, Carolina Reduzzi, William J. Gradishar, Amir Behdad, Massimo Cristofanilli	15
10	Correlation between different levels of HER2 expression in circulating tumor cells (cHER2 ratio) and metastatic behavior in stageIV_aggressive breast cancer. 2021 ·Journal of Clinical Oncology ·Paolo D’Amico, Carolina Reduzzi, Sara Gandini, Lorenzo Gerratana, Wenan Qiang, Qiang Zhang, (unknown), Youbin Zhang, Ami N. Shah, Andrew A. Davis, Saya Jacob, Elena Vagia, Firas Wehbe, Amir Behdad, Giuseppe Curigliano, Massimo Cristofanilli	5
11	Landscape of GATA3 mutations identified from circulating tumor DNA clinical testing and their impact on disease outcomes in estrogen receptor-positive (ER+) metastatic breast cancers treated with endocrine therapies. 2021 ·Journal of Clinical Oncology ·(unknown), Lorenzo Gerratana, Andrew A. Davis, Charles S. Dai, (unknown), A. John Iafrate, Bruce A. Chabner, Massimo Cristofanilli, Aditya Bardia	4
12	P33.06 Utilizing Serum Proteome to Understand Response and Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer 2021 ·Journal of Thoracic Oncology ·Young Kwang Chae, (unknown), Wade T. Iams, Michael S. Oh, Robert W. Lentz, (unknown), Joanna Roder, (unknown), Wonhee Hur, (unknown), Nisha Mohindra, Victoria Villaflor, Andrew A. Davis	1
13	Single-Cells Isolation and Molecular Analysis: Focus on HER2-Low CTCs in Metastatic Breast Cancer 2021 ·Cancers ·Paolo D’Amico, Carolina Reduzzi, Wenan Qiang, Youbin Zhang, Lorenzo Gerratana, Qiang Zhang, Andrew A. Davis, Ami N. Shah, (unknown), Giuseppe Curigliano, Massimo Cristofanilli	16
14	Abstract PS2-11: Ctc-her2+ a novel subset in stage IVaggressive: Molecular correlations, outcome and clinical characteristics in metastatic breast cancer 2021 ·Cancer Research ·Paolo D’Amico, Qiang Zhang, Lorenzo Gerratana, Youbin Zhang, Ami N. Shah, Carolina Reduzzi, Andrew A. Davis, Saya Jacob, Firas Wehbe, Amir Behdad, Giuseppe Curigliano, Massimo Cristofanilli	3
15	Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti–PD-1/PD-L1 Therapy in Non–Small-Cell Lung Cancer 2018 ·Clinical Lung Cancer ·Young Kwang Chae, Andrew A. Davis, Kirtee Raparia, Sarita Agte, Alan Pan, Nisha Mohindra, Victoria Villaflor, Francis J. Giles	87
16	The impact of circulating tumor cells (CTCs) detection in metastatic breast cancer (MBC): Implications of “indolent” stage IV disease (Stage IV_indolent). 2018 ·Journal of Clinical Oncology ·Andrew A. Davis, Jean‐Yves Pierga, Luc Dirix, Stefan Michiels, Alfred Rademaker, James M. Reuben, Tanja Fehm, Elisabetta Munzone, Mario Giuliano, José Vidal-Martínez, Dimitriοs Mavroudis, Salvatore Grisanti, Daniele Generali, José Á. García-Sáenz, Justin Stebbing, Sarah‐Jane Dawson, Paola Gazzaniga, François‐Clément Bidard, Massimo Cristofanilli	3
17	Biomarkers for PD-1/PD-L1 Blockade Therapy in Non–Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection? 2016 ·Clinical Lung Cancer ·Young Kwang Chae, Alan Pan, Andrew A. Davis, Kirtee Raparia, Nisha Mohindra, Maria Matsangou, Francis J. Giles	91
18	Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling 2015 ·Oncotarget ·Young Kwang Chae, Su Yun Chung, Andrew A. Davis, Benedito A. Carneiro, Sunandana Chandra, Jason Kaplan, Aparna Kalyan, Francis J. Giles	79
19	Metabolic Syndrome and Triple-Negative Breast Cancer: A New Paradigm 2011 ·International Journal of Breast Cancer ·Andrew A. Davis, Virginia Kaklamani	69
20	Effect of pyrolyzation temperature on wood-derived carbon and silicon carbide 2009 ·Journal of the European Ceramic Society ·(unknown), Susan Gentry, (unknown), Matthew T. Johnson, S. Xie, Andrew A. Davis, K. T. Faber	36

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact